Aveni Foundation

What it reported doing in 2025

THE AVENI FOUNDATION REPORTED THE PERFORMANCE OF TWO CLINICAL STUDIES:1. Compassionate Use of Intravenous DNG64-CAR-V Tumor-Targeted Retrovector Bearing a Cytocidal Dominant Negative Cyclin G1 Inhibitor for Advanced Sarcoma, Pancreatic Cancer, Non-small Cell Lung Cancer, Breast Cancer, Cholangiocarcinoma, Basal Cell Carcinoma, Ovarian Carcinoma (Single Use INDs)2. Blessed: Expanded Access for DNG64-CAR-V for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast for an Intermediate Size Population (NCT04091295)Thirty-two patients were enrolled, 18 sarcoma, 5 pancreatic ductal adenocarcinoma, 1 non-small cell lung cancer, 3 breast carcinoma, 1 prostate cancer, 1 cholangiocarcinoma, 1 basal cell carcinoma, 1 ovarian cancer, and 1 glioblastoma. Sixteen patients were enrolled in Study 1 single patient IND, 16 patients were enrolled in Study 2. Three patients were initially enrolled in Study 2 and later enrolled in Study 1. Twenty-seven of 32 enrolled patients were treated with DNG64-CAR-V either as monotherapy or in combination with FDA approved cancer therapies. Four of the 27 patients treated with DNG64-CAR-V and FDA approved drugs were also treated with either SNK01 autologous enhanced NK cell therapy or SNK02 allogeneic enhanced NK cell therapy.Nine of 15 (60%) patients treated with DNG64-CAR-V + FDA approved drugs are alive 1-71 months from treatment initiation, 2 with breast cancer are alive in complete remission, 1 with pancreatic cancer is alive with progressive disease, 3 with sarcoma are alive with either complete response s/p surgical resection, partial response or stable disease, 1 with basal cell carcinoma is alive with partial response, 1 with ovarian cancer is alive with partial response, and 1 with glioblastoma is alive receiving first cycle of treatment. Two patients with Stage 4 pancreatic adenocarcinoma who initially failed standard chemotherapy and who were treated with DNG64-CAR-V and low dose chemo lived 8.5-9.5 months, which is similar to the median survival duration of pancreatic cancer patients receiving first line therapy. One patient with metastatic liposarcoma and one patient with metastatic leiomyosarcoma who were treated with DNG64-CAR-V and low dose chemo lived 12 months, which is similar to the median survival duration of sarcoma patients receiving first line therapy.

Financial Efficiency

• Mission deployment rate: 100%; rating input score 100
• Program expense ratio: 80.1%; rating input score 80
• Fundraising efficiency: Limited

Transparency & Controls

• Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
• Pay-setting controls: Limited
• Foreign activity oversight: Limited
• Grant itemization coverage: Limited
• Major donor itemization: Yes; rating input score 100
• Related-party transparency: Limited

Accountability

• Independent voting board: 100%; rating input score 100; 64th percentile among comparable filings
• Governance controls: 5 of 7 controls in place; rating input score 71
  • Conflict-of-interest policy: Pass
  • Whistleblower policy: Pass
  • Document-retention policy: Pass
  • CEO compensation review process: NotApplicable
  • Other executive compensation review process: NotApplicable
  • Form 990 shared with the board: Pass
  • Board meeting minutes documented: Pass
  • Audit committee oversight: Missing
  • Independent financial-statement audit: Fail

Sustainability

• Operating margin: -162.8%; rating input score 1; 1st percentile among comparable filings
• Total-asset coverage ratio: 1.03; rating input score 42; 42nd percentile among comparable filings
• Liabilities to assets ratio: 0; rating input score 51; 51st percentile among comparable filings
• Officer compensation ratio: 21.4%; rating input score 17; 17th percentile among comparable filings

Growth

• Program expense growth: 22.8% per year; rating input score 100; 85th percentile among comparable filings
• Revenue growth: 24.7% per year; rating input score 100; 90th percentile among comparable filings
• Asset growth: 32% per year; rating input score 100; 91st percentile among comparable filings